IRIS
CASTIGLIONE, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.579
AS - Asia 4.467
EU - Europa 4.010
SA - Sud America 1.313
AF - Africa 110
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 2
Totale 19.492
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.218
SG - Singapore 1.969
RU - Federazione Russa 1.675
BR - Brasile 1.092
CN - Cina 1.068
IT - Italia 913
VN - Vietnam 572
GB - Regno Unito 344
DE - Germania 276
HK - Hong Kong 266
CA - Canada 254
FI - Finlandia 132
IE - Irlanda 130
IN - India 100
TR - Turchia 94
FR - Francia 93
AR - Argentina 80
BD - Bangladesh 74
MX - Messico 74
SE - Svezia 72
PL - Polonia 71
UA - Ucraina 71
ID - Indonesia 59
NL - Olanda 58
ES - Italia 49
ZA - Sudafrica 47
IL - Israele 42
EC - Ecuador 40
IQ - Iraq 40
AT - Austria 38
PK - Pakistan 38
JP - Giappone 35
AE - Emirati Arabi Uniti 25
LT - Lituania 23
PY - Paraguay 23
CO - Colombia 22
UZ - Uzbekistan 20
MA - Marocco 19
VE - Venezuela 16
PE - Perù 14
RO - Romania 13
CL - Cile 12
SA - Arabia Saudita 11
BE - Belgio 10
EG - Egitto 10
DO - Repubblica Dominicana 9
KE - Kenya 9
UY - Uruguay 9
AU - Australia 7
DK - Danimarca 7
IR - Iran 6
TN - Tunisia 6
CR - Costa Rica 5
CZ - Repubblica Ceca 5
DZ - Algeria 5
JO - Giordania 5
AL - Albania 4
AZ - Azerbaigian 4
CH - Svizzera 4
GY - Guiana 4
MY - Malesia 4
TT - Trinidad e Tobago 4
BY - Bielorussia 3
GT - Guatemala 3
HU - Ungheria 3
KR - Corea 3
KZ - Kazakistan 3
NI - Nicaragua 3
NP - Nepal 3
OM - Oman 3
PA - Panama 3
SN - Senegal 3
TW - Taiwan 3
AM - Armenia 2
AO - Angola 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
BN - Brunei Darussalam 2
CI - Costa d'Avorio 2
GD - Grenada 2
GR - Grecia 2
HN - Honduras 2
JM - Giamaica 2
KW - Kuwait 2
LV - Lettonia 2
MD - Moldavia 2
MG - Madagascar 2
NZ - Nuova Zelanda 2
TH - Thailandia 2
TL - Timor Orientale 2
AD - Andorra 1
AF - Afghanistan, Repubblica islamica di 1
BH - Bahrain 1
BO - Bolivia 1
CW - ???statistics.table.value.countryCode.CW??? 1
ET - Etiopia 1
EU - Europa 1
GE - Georgia 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
Totale 19.476
Salva come PNG Salva come JPEG
Città #
Dallas 2.428
Singapore 1.083
Chicago 851
Los Angeles 574
Ashburn 544
Beijing 483
Salt Lake City 393
Moscow 313
Hong Kong 255
Buffalo 235
Tampa 202
Ho Chi Minh City 195
Chandler 181
Elk Grove Village 163
New York 139
Dublin 130
São Paulo 124
Hanoi 121
Boardman 119
Wilmington 111
The Dalles 108
Hefei 106
Munich 102
Beauharnois 89
Milan 88
Fairfield 84
Pisa 82
San Mateo 82
Sterling 81
Lancaster 72
Rome 71
Santa Clara 71
Cambridge 65
Seattle 63
Warsaw 61
Florence 60
London 58
Houston 57
Istanbul 57
Montreal 57
Miami 55
Denver 52
Poplar 52
Helsinki 51
Dulles 48
Phoenix 48
Brooklyn 47
Stockholm 46
Atlanta 44
Orem 44
Ottawa 43
Frankfurt am Main 41
Lappeenranta 41
Portsmouth 40
Stevenage 38
Chennai 36
Rio de Janeiro 35
Turku 35
Johannesburg 34
Tokyo 34
Nuremberg 33
Southend 33
Tel Aviv 33
Toronto 33
Detroit 32
Falls Church 32
Kansas City 31
Boston 30
Council Bluffs 30
Lawrence 30
Mexico City 30
Woodbridge 30
Belo Horizonte 27
Ankara 26
Jacksonville 26
Manchester 25
Washington 25
Amsterdam 24
Da Nang 24
Lucca 24
Pittsburgh 24
Porto Alegre 24
Hangzhou 22
Bologna 21
Guangzhou 21
Palermo 19
Tashkent 19
Dong Ket 18
Guayaquil 18
San Francisco 18
Curitiba 17
Livorno 17
Genoa 16
Haiphong 16
Shanghai 16
Brasília 15
New Delhi 15
Paris 15
Querétaro 15
Vienna 15
Totale 11.961
Salva come PNG Salva come JPEG
Nome #
Prognostic value of soluble ST2 in AL and TTR cardiac amyloidosis: a multicenter study 1.794
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.600
High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study 662
Patient-reported outcome measures for transthyretin cardiac amyloidosis: the ITALY study 551
A simple echocardiographic score to rule out cardiac amyloidosis 307
Bidirectional Relationship Between Cancer and Heart Failure: Insights on Circulating Biomarkers 281
A simple echocardiographic score to rule out cardiac amyloidosis 258
[Central apneas and cardiovascular diseases] 253
Using co-creation to develop a cardiology online open course: an effective approach for implementing digital learning 253
[Treatment of cardiac fibrosis: from neurohormonal antagonists to CAR-T cells] 231
Effect of Sex on Reverse Remodeling in Chronic Systolic Heart Failure 215
Neurohormonal modulation for treatment of cardiac involvement in dystrophinopathies and mitochondrial disease 213
Oxidative stress and inflammation in the evolution of heart failure: From pathophysiology to therapeutic strategies 210
The extent and location of late gadolinium enhancement predict defibrillator shock and cardiac mortality in patients with non-ischaemic dilated cardiomyopathy 208
Wild-type transthyretin cardiac amyloidosis is not rare in elderly subjects: the CATCH screening study 206
Atrial amyloidosis: mechanisms and clinical manifestations 204
Unveiling a sudden unexplained death case by whole exome sequencing and bioinformatic analysis 203
Biomarkers for the diagnosis and management of heart failure 203
Myocardial salvage is increased after sympathetic renal denervation in a pig model of acute infarction 198
Biomarkers for the diagnosis and management of heart failure: New frontiers 194
Cardiovascular disease and COVID-19: les liaisons dangereuses 192
Eligibility for vericiguat in a real‐world, contemporary heart failure population 190
Patients with cardiac amyloidosis have a greater neurohormonal activation than those with non-amyloidotic heart failure 188
Biomarkers for the diagnosis and management of heart failure: Natriuretic peptides 185
Myocardial Infarction Following COVID-19 Vaccine Administration: Post Hoc, Ergo Propter Hoc? 184
Role of Imaging in Cardiomyopathies 181
Prognostic value of right ventricular refractory period heterogeneity in Type-1 Brugada electrocardiographic pattern 181
Clinical and prognostic significance of central and obstructive apnoeas in patients with transthyretin cardiac amyloidosis 179
Beta-blocking patients with cardiac amyloidosis: Adelante cum juicio 179
Cardiac magnetic resonance in patients with muscular dystrophies 179
Approccio critico all’interpretazione dei trial cardiovascolari con risultati neutri o negativi 174
Valvular heart disease in patients with cardiac amyloidosis 171
Disease features and management of cardiomyopathies in women 171
Molecular autopsy of sudden cardiac death in the genomics era 170
Multiparametric Echocardiography Scores for the Diagnosis of Cardiac Amyloidosis 168
Biomarkers in heart failure clinical trials. A review from the Biomarkers Working Group of the Heart Failure Association of the European Society of Cardiology 167
Oxidative stress and inflammation: determinants of anthracycline cardiotoxicity and possible therapeutic targets 166
Haemodynamic forces predicting remodelling and outcome in patients with heart failure treated with sacubitril/valsartan 165
Scared to Death: Emotional Stress Causing Fatal Myocardial Infarction With Nonobstructed Coronary Arteries in Women 164
Biopsy Evidence of Sequential Transthyretin and Immunoglobulin Light-Chain Cardiac Amyloidosis in the Same Patient 164
RNA-targeting and gene editing therapies for transthyretin amyloidosis 160
Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis 158
Healthy hearts at hectic pace: From daily life stress to abnormal cardiomyocyte function and arrhythmias 156
Targeting Cyclic Guanosine Monophosphate to Treat Heart Failure: JACC Review Topic of the Week 156
Multi-chamber speckle tracking imaging and diagnostic value of left atrial strain in cardiac amyloidosis 155
Tissue Characterization in Cardiac Amyloidosis 154
Valve disease in cardiac amyloidosis: an echocardiographic score 153
Sex differences in transthyretin cardiac amyloidosis 151
Effects of sacubitril-valsartan on remodelling, fibrosis and mitochondria in a murine model of isoproterenol-induced left ventricular dysfunction 151
Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy 150
The place of vericiguat in the landscape of treatment for heart failure with reduced ejection fraction 150
Cardiovascular toxicity from therapies for light chain amyloidosis 149
Current and emerging drug targets in heart failure treatment 148
Pathophysiology of Cardiac Amyloidosis 147
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 145
The Role of Scintigraphy with Bone Radiotracers in Cardiac Amyloidosis 143
Cardiac Amyloidosis: How Its Epidemiology is Changing 142
Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers 139
Coronary Artery Anomalies 139
Characteristics of patients with suspected cardiac amyloidosis in Tuscany and Umbria: Insights from the cardiac amyloidosis RegistRY (CARRY) 135
Intact fibroblast growth factor 23 in heart failure with reduced and mildly reduced ejection fraction 135
Etiological Treatment of Cardiac Amyloidosis: Standard of Care and Future Directions 134
Prevalence and functional impact of chronotropic incompetence in amyloid cardiomyopathy: a multicentre analysis 134
Pathophysiological Rationale and Clinical Evidence for Neurohormonal Modulation in Heart Failure with Preserved Ejection Fraction 133
Right heart failure in left heart disease: imaging, functional, and biochemical aspects of right ventricular dysfunction 133
Transthyretin Stabilizers and Seeding Inhibitors as Therapies for Amyloid Transthyretin Cardiomyopathy 133
Obstructive sleep apnea and cardiovascular diseases 131
Use of biomarkers to diagnose and manage cardiac amyloidosis 131
Estimated total amyloid burden from 18F-florbetaben positron emission tomography predicts all-cause mortality in light-chain cardiac amyloidosis 130
Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study 129
What Is Hidden Behind Inferior Negative T Waves: Multiple Cardiac Glomangiomas 128
Biomarkers of HFpEF: Natriuretic Peptides, High-Sensitivity Troponins and Beyond 127
Chest pain after elective percutaneous coronary intervention as trigger of takotsubo syndrome-a case report 124
Treatment of cardiac transthyretin amyloidosis: an update 124
Rarefaction of Blood, But Not Lymphatic Capillaries, in Patients With Cardiac Amyloidosis 120
Current and emerging treatment options for transthyretin amyloid cardiomyopathy 118
PET and Cardiac Amyloidosis 118
Do we need to EVALUATE multiple biomarkers and/or the same biomarkers multiple times in patients with heart failure? 118
Positron emission tomography in cardiac amyloidosis: current evidence and future directions 117
Critical Reading of cardiovascular trials with neutral or negative results 115
Gamma-glutamyltransferase independently predicts mortality and hospitalization for heart failure in cardiac transthyretin amyloidosis 113
Safety and Efficacy of Amiodarone in a Patient With COVID-19 112
Stroke in ATTR cardiac amyloidosis: Does only rhythm matter? 111
Cardiac Biomarkers in Patients With Suspected Amyloid (Transthyretin) Cardiomyopathy: Which Cut-Offs? 108
Tetrameric Transthyretin as a Protective Factor Against Alzheimer’s Disease 108
Head-to-head comparison between recommendations by the ESC and ACC/AHA/HFSA heart failure guidelines 107
Is targeting cyclic guanosine monophosphate by vericiguat effective to treat ischaemic heart failure with reduced ejection fraction? Yes, it is 105
Cost-effectiveness of transthyretin cardiac amyloidosis screening and treatment: A Dilemma for the clinician 103
Left ventricular wall thickness and severity of cardiac disease in women and men with transthyretin amyloidosis 101
The unbearable underreporting of comorbidities in heart failure clinical trials 101
The Mayo ATTR‐CM score versus other diagnostic scores and cardiac biomarkers in patients with suspected cardiac amyloidosis 100
Safety and Tolerability of Neurohormonal Antagonism in Cardiac Amyloidosis 100
Prevalence and clinical outcomes of isolated or combined moderate to severe mitral and tricuspid regurgitation in patients with cardiac amyloidosis 99
The Left Ventricular Mass-to-Strain Ratio: Enough to Differentiate ATTR From AL Cardiac Amyloidosis? 98
Right ventricular to pulmonary artery coupling and outcome in patients with cardiac amyloidosis 92
Characterization of Phenotypic Variability in Becker Muscular Dystrophy for Clinical Practice and Towards Trial Readiness: A Two-Years Follow up Study 92
The Journey of Human Transthyretin: Synthesis, Structure Stability, and Catabolism 92
Heart Failure Management in Cardiac Amyloidosis: Towards a Paradigm Shift 91
sST2 for Outcome Prediction in Acute Heart Failure: Which Is the Best Cutoff? 91
Transesophageal Echocardiography Before Elective Direct Current Cardioversion in Cardiac Amyloidosis: Too Soon to Discard It? 83
Totale 19.282
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.570
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.570
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021233 0 0 0 0 0 26 22 24 39 24 49 49
2021/2022544 45 67 17 39 25 62 45 94 58 50 7 35
2022/2023563 33 61 23 50 58 71 23 49 103 22 51 19
2023/2024756 43 15 140 74 47 65 53 31 27 47 31 183
2024/20258.157 51 97 231 132 304 256 611 1.146 434 1.070 2.199 1.626
2025/20269.135 840 2.001 2.131 2.031 1.486 646 0 0 0 0 0 0
Totale 19.611